Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification and Validation of the Immune Subtypes of Lung Adenocarcinoma: Implications for Immunotherapy

3 Jul 2020

Abstract excerpt

Lung adenocarcinoma (LUAD) is a devastating disease with poor patient survival. Cancer immunotherapy has revolutionized the treatment of LUAD, but only a limited number of patients effectively respond to this treatment. Thus, the work to elucidate the LUAD immune heterogeneity could be crucial in developing new immunotherapeutic strategies with better efficacy. Non-negative matrix factorization-based...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Ferroptosis and cancer prognosis
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32719796
DOI: 10.3389/fcell.2020.00550

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification and Validation of the Immune Subtypes of Lung Adenocarcinoma: Implications for ImmunotherapyPMID 32719796Read ↗

Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy.Semantic proximity Read ↗

Identification of lung adenocarcinoma subtypes and predictive signature for prognosis, immune features, and immunotherapy based on immune checkpoint genesSemantic proximity Read ↗

An immune indicator based on BTK and DPEP2 identifies hot and cold tumors and clinical treatment outcomes in lung adenocarcinomaSemantic proximity Read ↗

Unraveling the Expression Patterns of Immune Checkpoints Identifies New Subtypes and Emerging Therapeutic Indicators in Lung AdenocarcinomaSemantic proximity Read ↗

Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma.Semantic proximity Read ↗

Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosisSemantic proximity Read ↗

Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung AdenocarcinomaSemantic proximity Read ↗

Multi-omics Data Analyses Construct TME and Identify the Immune-Related Prognosis Signatures in Human LUADSemantic proximity Read ↗

Immune clustering reveals molecularly distinct subtypes of lung adenocarcinomaSemantic proximity Read ↗

Integration of multi-omics profiling reveals an epigenetic-based molecular classification of lung adenocarcinoma: implications for drug sensitivity and immunotherapy response predictionSemantic proximity Read ↗

Identification of prognostic molecular subtypes and model based on CD8+ T cells for lung adenocarcinomaSemantic proximity Read ↗

Machine-learning-guided single-cell transcriptomic interrogation identifies biomarkers and candidate therapeutics for immune-cold lung adenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.